Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in:

03.08.2020 | Original Paper

A Pilot Study to Evaluate a Novel Pre-exposure Prophylaxis Peer Outreach and Navigation Intervention for Women at High Risk for HIV Infection

verfasst von: Oni J. Blackstock, Joey Platt, Sarit A. Golub, Amarachi R. Anakaraonye, Brianna L. Norton, Suzan M. Walters, Jae M. Sevelius, Chinazo O. Cunningham

Erschienen in: AIDS and Behavior | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Pre-exposure prophylaxis (PrEP) uptake remains woefully low among U.S. women at high risk for HIV acquisition. We evaluated a pilot intervention which involved Peers providing brief PrEP education and counseling at mobile syringe exchange sites and at sex worker and syringe exchange drop-in centers followed by navigation to PrEP care. Peers recruited English-proficient, self-identified women (i.e., cisgender and transgender women and persons with other transfeminine identities) over a 3-month period and delivered the intervention to 52 HIV-negative/status unknown participants. Thirty-eight participants (73.1%) reported PrEP interest, 27 (51.9%) accepted the offer of a PrEP appointment, 13 (25.0%) scheduled a PrEP appointment, 3 (5.8%) attended an initial PrEP appointment, and none were prescribed PrEP. We found a gap between PrEP interest and connecting women to PrEP care. Further study is needed to understand this gap, including exploring innovative approaches to delivering PrEP care to women at highest risk for HIV.
Literatur
1.
Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–e519519.PubMedPubMedCentral
2.
Thomson KA, Baeten JM, Mugo NR, Bekker L-G, Celum CL, Heffron R. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS. 2016;11(1):18–26.PubMedPubMedCentral
3.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedPubMedCentral
4.
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMed
5.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedPubMedCentral
6.
Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDs. 2015;29(2):102–10.PubMedPubMedCentral
7.
Sevelius JM, Keatley J, Calma N, Arnold E. 'I am not a man': trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11(7–8):1060–75.PubMed
8.
Flash CA, Stone VE, Mitty JA, Mimiaga MJ, Hall KT, Krakower D, et al. Perspectives on HIV prevention among urban Black women: a potential role for HIV pre-exposure prophylaxis. AIDS Patient Care STDs. 2014;28(12):635–42.PubMedPubMedCentral
9.
Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. J Int AIDS Soc. 2016;19(6):21105.PubMedPubMedCentral
10.
Eaton LA, Matthews DD, Driffin DD, Bukowski L, Wilson PA, Stall RD, et al. A multi-US city assessment of awareness and uptake of pre-exposure prophylaxis (PrEP) for HIV prevention among Black men and transgender women who have sex with men. Prev Sci. 2017;18:505–16.PubMedPubMedCentral
11.
Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.PubMedPubMedCentral
12.
Mera Giler R, Magnusen D, Trevor H, editors. Changes in Truvada for HIV pre-exposure prophylaxis utilization in the USA: 2012–2016. 9th International AIDS Society Conference on HIV Science (2017).
13.
Wu H, Mendoza MC, Huang YIA, Hayes T, Smith DK, Hoover KW. Uptake of HIV preexposure prophylaxis among commercially insured persons—United States, 2010–2014. Clin Infect Dis. 2016;64(2):144–9.PubMed
14.
Ya-lin AH. HIV preexposure prophylaxis, by race and ethnicity—United States, 2014–2016. MMWR Morb Mortal Wkly Rep. 2018;67:1147.
15.
Kuhns LM, Reisner SL, Mimiaga MJ, Gayles T, Shelendich M, Garofalo R. Correlates of PrEP indication in a multi-site cohort of young HIV-Uninfected Transgender Women. AIDS Behav. 2015;20:1470.
16.
17.
Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006–2017. Am J Public Health. 2019;109(1):e1–e8.PubMedPubMedCentral
18.
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic. JAMA. 2019;321(9):844.PubMed
19.
20.
Walters SM, Rivera AV, Reilly KH, Anderson BJ, Bolden B, Wogayehu A, et al. Exchange sex among persons who inject drugs in the New York metropolitan area: the importance of local context, gender and sexual identity. AIDS Behav. 2018;22:2773.PubMed
21.
Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156(8):541–50.PubMedPubMedCentral
22.
Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008;12(1):1–17.PubMed
23.
Blackstock OJ, Frew P, Bota D, Vo-Green L, Parker K, Franks J, et al. Perceptions of community HIV/STI risk among U.S women living in areas with high poverty and HIV prevalence rates. J Health Care Poor Underserved. 2015;26(3):811–23.PubMedPubMedCentral
24.
De Santis JP. HIV infection risk factors among male-to-female transgender persons: a review of the literature. J Assoc Nurses AIDS Care. 2009;20(5):362–72.PubMed
25.
Adimora AA, Schoenbach VJ, Taylor EM, Khan MR, Schwartz RJ, Miller WC. Sex ratio, poverty, and concurrent partnerships among men and women in the United States: a multilevel analysis. Ann Epidemiol. 2013;23(11):716–9.PubMedPubMedCentral
26.
Li Y, Marshall CM, Rees HC, Nunez A, Ezeanolue EE, Ehiri JE. Intimate partner violence and HIV infection among women: a systematic review and meta-analysis. J Int AIDS Soc. 2014;17(1):18845.PubMedPubMedCentral
27.
Walters SM, Reilly KH, Neaigus A, Braunstein S. Awareness of pre-exposure prophylaxis (PrEP) among women who inject drugs in NYC: the importance of networks and syringe exchange programs for HIV prevention. Harm Reduct J. 2017;14(1):40.PubMedPubMedCentral
28.
Wilson EC, Jin H, Liu A, Raymond HF. Knowledge, indications and willingness to take pre-exposure prophylaxis among transwomen in San Francisco, 2013. PLoS ONE. 2015;10(6):e0128971.PubMedPubMedCentral
29.
Bazzi AR, Biancarelli DL, Childs E, Drainoni M-L, Edeza A, Salhaney P, et al. Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. AIDS Patient Care STDs. 2018;32:529.PubMedPubMedCentral
30.
Park CJ, Taylor TN, Gutierrez NR, Zingman BS, Blackstock OJ. Pathways to HIV pre-exposure prophylaxis among women prescribed PrEP at an urban sexual health clinic. J Assoc Nurses AIDS Care. 2019;30:321.PubMed
31.
Rael CT, Martinez M, Giguere R, Bockting W, Maccrate C, Mellman W, et al. Barriers and facilitators to oral PrEP use among transgender women in New York city. AIDS Behav. 2018;22:3627.PubMedPubMedCentral
32.
Park C, Taylor T, Rios N, Khedimi R, Weiss C, Dolce E, et al., (eds). Perspectives of women prescribed HIV pre-exposure prophylaxis (PrEP). Open forum infectious diseases. Oxford: Oxford University Press; 2017.
33.
Braksmajer A, Senn TE, McMahon J. The potential of pre-exposure prophylaxis for women in violent relationships. AIDS Patient Care STDs. 2016;30(6):274–81.PubMedPubMedCentral
34.
Sevelius JM, Keatley J, Calma N, Arnold E. ‘I am not a man’: trans-specific barriers and facilitators to PrEP acceptability among transgender women. Glob Public Health. 2016;11(7–8):1060–75.PubMed
35.
Bradley E, Forsberg K, Betts JE, DeLuca JB, Kamitami E, Porter SE, et al. Factors affecting pre-exposure prophylaxis implementation for women in the United States: a systematic review. J Women's Health. 2019;28:1272.
36.
Aaron E, Blum C, Seidman D, Hoyt MJ, Simone J, Sullivan M, et al. Optimizing delivery of HIV preexposure prophylaxis for women in the United States. AIDS Patient Care STDs. 2018;32(1):16–23.PubMedPubMedCentral
37.
Bradford JB, Coleman S, Cunningham W. HIV system navigation: an emerging model to improve HIV care access. AIDS Patient Care STDs. 2007;21(s1):S49–S58.PubMed
38.
Higa DH, Marks G, Crepaz N, Liau A, Lyles CM. Interventions to improve retention in HIV primary care: a systematic review of U.S. studies. Curr HIV/AIDS Rep. 2012;9(4):313–25.PubMedPubMedCentral
39.
Rajabiun S, Cabral H, Tobias C, Relf M. Program design and evaluation strategies for the special projects of National Significance Outreach Initiative. AIDS Patient Care STDs. 2007;21(s1):9–19.
40.
Mayer KH, Chan PA, Patel R, Flash CA, Krakower DS. Evolving models and ongoing challenges for HIV pre-exposure prophylaxis implementation in the United States. J Acquir Immune Deficienc Syndr (1999). 2018;77(2):119.
41.
42.
43.
44.
45.
DiClemente RJ, Crosby RA, Kegler MC. Emerging theories in health promotion practice and research. Hoboken: Wiley; 2009.
46.
Merriam SB, Bierema LL. Adult learning: linking theory and practice. Hoboken: Wiley; 2013.
47.
48.
49.
Golub S (2016). Understanding Implementation of HIV Prevention Navigation in STD Clinics [National Institutes of Health Grant R01MH106380–02S1].
50.
The Center Advancing LGBT Health Colorado (2014) Colorado Transgender Health Survey
51.
National Institute on Drug Abuse. HIV Risk Behaviors/ Perception of Risks Questionnaire [Seek, Test, Treat and Retain for Vulnerable Populations: Data Harmonization Measure] (2015).
52.
Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284–92.PubMed
53.
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder. Arch Intern Med. 2006;166(10):1092.PubMed
54.
Shakil A, Bardwell J, Sherin K, Sinacore JM, Zitter R, Kindratt TB. Development of Verbal HITS for intimate partner violence screening in family medicine. Fam Med. 2014;46(3):180–5.PubMed
55.
Golub S. Intervention to Enhance PrEP Uptake and Adherence in a Community-based Setting [National Institutes of Health Grant R01AA022067] (2012).
56.
Chinazo OC, John-Paul S, Xuan L, Daliah H, Nancy LS. Medical and support service utilization in a medical program targeting marginalized HIV-infected Individuals. J Health Care Poor Underserved. 2008;19(3):981–90.
57.
Greenfield L, Brady JV, Besteman KJ, De Smet A. Patient retention in mobile and fixed-site methadone maintenance treatment. Drug Alcohol Depend. 1996;42(2):125–31.PubMed
58.
Hall G, Neighbors CJ, Iheoma J, Dauber S, Adams M, Culleton R, et al. Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. J subst Abuse Treat. 2014;46(4):511–5.PubMed
59.
Maru DSR, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, et al. Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav. 2008;12(2):284–93.PubMed
60.
Roth AM, Aumaier BL, Felsher MA, Welles SL, Martinez-Donate AP, Chavis M, et al. An exploration of factors impacting preexposure prophylaxis eligibility and access among syringe exchange users. Sex Transm Dis. 2018;45(4):217–21.PubMed
61.
Strathdee SA, Sherman SG. The role of sexual transmission of HIV infection among injection and non-injection drug users. J Urban Health. 2003;80(3):7–14.
62.
Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet. 2001;357(9266):1397–401.PubMed
63.
Hill MJ, Holt M, Hanscom B, Wang Z, Cardenas-Turanzas M, Latkin C. Gender and race as correlates of high risk sex behaviors among injection drug users at risk for HIV enrolled in the HPTN 037 study. Drug Alcohol Depend. 2018;183:267–74.PubMedPubMedCentral
64.
Neaigus A, Reilly KH, Jenness SM, Hagan H, Wendel T, Gelpi-Acosta C. Dual HIV risk: receptive syringe sharing and unprotected sex among HIV-negative injection drug users in New York City. AIDS Behav. 2013;17(7):2501–9.PubMed
65.
Caponi M, Burgess C, Leatherwood A, Molano LF. Demographic characteristics associated with the use of HIV pre-exposure prophylaxis (PrEP) in an urban, community health center. Prev Med Rep. 2019;15:100889.PubMedPubMedCentral
66.
Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham C, Patel V, et al. Primary care physicians’ willingness to prescribe HIV pre-exposure prophylaxis for people who inject drugs. AIDS Behav. 2016;21:1025.
67.
Calabrese SK, Earnshaw VA, Underhill K, Krakower DS, Magnus M, Hansen NB, et al. Prevention paradox: medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need. J Int AIDS Soc. 2018;21(6):e25147.PubMedPubMedCentral
Metadaten
Titel
A Pilot Study to Evaluate a Novel Pre-exposure Prophylaxis Peer Outreach and Navigation Intervention for Women at High Risk for HIV Infection
verfasst von
Oni J. Blackstock
Joey Platt
Sarit A. Golub
Amarachi R. Anakaraonye
Brianna L. Norton
Suzan M. Walters
Jae M. Sevelius
Chinazo O. Cunningham
Publikationsdatum
03.08.2020
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 5/2021
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-02979-y

Weitere Artikel der Ausgabe 5/2021

Lifetime Burden of Incarceration and Violence, Internalized Homophobia, and HIV/STI Risk Among Black Men Who Have Sex with Men in the HPTN 061 Study

  • Original Paper

Black and Latino Persons Living with HIV Evidence Risk and Resilience in the Context of COVID-19: A Mixed-Methods Study of the Early Phase of the Pandemic

  • Zur Zeit gratis
  • COVID-19
  • Original Paper

Web-Based Cognitive Training to Improve Working Memory in Persons with Co-Occurring HIV Infection and Cocaine Use Disorder: Outcomes from a Randomized Controlled Trial

  • Original Paper

Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIV

  • Original Paper

Biometric Registration to an HIV Research Study may Deter Participation

  • Original Paper

Is HIV Post-test Counselling Aligned with Universal Test and Treat Goals? A Qualitative Analysis of Counselling Session Content and Delivery in South Africa

  • Original Paper

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Antibiotika bei Bakteriämie – 7 versus 14 Tage

  • 21.01.2025
  • Sepsis
  • Nachrichten

Eine Bakteriämie lässt sich mit einer einwöchigen Antibiotikatherapie zumeist gut in den Griff bekommen: Die Sterberate ist nicht höher als unter zweiwöchiger Behandlung, zeigt eine Vergleichsstudie mit hospitalisierten Erkrankten. Allerdings muss die Therapie bei fast jedem Vierten verlängert werden.

"Die Erektionsstörung ist keine isolierte Erkrankung"

Werden Erektionsstörungen gut behandelt (und das ist möglich), steigt die Lebensqualität enorm. Tipps für eine gute Kommunikation mit den Patienten gibt Androloge Dr. med. Jann-Frederik Cremers in dieser Folge. Welche Fragen sollten gestellt und an welche Ursachen gedacht werden? Und was ist zu tun, wenn PDE-5-Hemmer und Lebensstilveränderungen nicht ausreichend wirken?

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise